What symptoms and screening options exist for anal cancer?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Anal cancer most commonly presents with rectal bleeding, anal pain or a palpable mass; other frequent signs include nonhealing ulcers, fistulae, itching, discharge and changes in bowel habits (diarrhea or constipation) [1] [2] [3]. For people at elevated risk (especially people with HIV, men who have sex with men, those with prior cervical/vulvar cancer or persistent high‑risk HPV), screening strategies used or recommended by multiple expert bodies include digital anorectal (rectal) examination (DRE/DARE), anal cytology (“anal Pap”), high‑risk HPV testing and high‑resolution anoscopy (HRA) for diagnostic follow‑up [4] [5] [6].
1. Symptoms that push clinicians to investigate: bleeding, pain and lumps
Clinicians report that the most common presenting complaints are bleeding from the anus, anal or rectal pain, a nonhealing ulcer or fistula, and a mass felt on exam; some patients also have itching, discharge, or bowel changes such as diarrhea or constipation [1] [2] [3]. Multiple cancer centers and specialty reviews emphasize that these symptoms overlap with far more common benign conditions (hemorrhoids, fissures, infections), which contributes to delays and occasional misdiagnosis [2] [7].
2. The basic diagnostic workup: look, feel, then biopsy
Guidance is consistent: an evaluation begins with history and a focused physical exam including a digital rectal exam and anoscopy with inspection of the anal canal; any suspicious lesion requires biopsy for histologic diagnosis [1] [8] [9]. Imaging (MRI, endoanal ultrasound) is commonly used for staging and assessment after treatment but tissue biopsy is the diagnostic standard [8].
3. Who experts consider “high risk” and why screening focuses there
Because anal cancer is uncommon in the general population, most organizations recommend targeting screening to higher‑risk groups—people living with HIV (especially MSM and transgender women), people with prior lower genital‑tract HSIL or cancer, transplant recipients, or those with persistent high‑risk HPV—rather than routine population screening [5] [4] [6]. The ANCHOR and related studies influenced this shift by showing that treating high‑grade anal lesions reduces cancer risk in people with HIV, prompting federal and society recommendations to expand screening in those groups [10] [11].
4. Screening tools in use — strengths and tradeoffs
Anal cytology (anal Pap) is widely recommended as a first‑line screening test by several societies; it detects cellular abnormalities and can be paired with high‑risk HPV testing or cotesting to improve triage [12] [13]. High‑risk HPV testing (including HPV16 genotyping) is used either alone or with cytology; HRA is the diagnostic follow‑up for abnormal screening results and allows targeted biopsy and treatment [4] [13]. Digital anorectal exam remains a low‑tech, universally endorsed element of screening and surveillance [5] [14].
5. Evidence gaps, harms and implementation limits
Guideline panels note there are insufficient comparative data to endorse one single screening algorithm for all groups and emphasize tradeoffs: screening may find treatable precancers but also generate anxiety, unnecessary procedures and capacity challenges because HRA services are limited [13] [15]. Some centers advise annual DRE and organ‑specific screening intervals (e.g., yearly for many people with HIV) while others suggest 1–3 year cytology intervals depending on risk—reflecting divergent recommendations and limited long‑term population‑level mortality data [5] [16].
6. Prevention — vaccination and risk reduction
HPV vaccination prevents infection with the common oncogenic types (including HPV‑16) and is identified by guideline authors as a primary prevention tool, although vaccination does not reverse established anal HPV infection [5] [17]. Several screening advisories also pair screening recommendations with advocacy for smoking cessation and HPV vaccination as part of comprehensive prevention strategies [12].
7. What patients should do now — pragmatic next steps
Anyone with persistent rectal bleeding, new anal pain, a lump, nonhealing ulcer or unexplained discharge should seek medical evaluation with DRE/anoscopy and, if indicated, biopsy [1] [9]. People in high‑risk categories (especially adults with HIV, people with prior lower genital tract HSIL/cancer, those with anal warts or immunosuppression) should discuss targeted screening (anal cytology ± hrHPV testing), the local availability of HRA and an individualized plan with their clinician [6] [4].
Limitations and transparency: this summary synthesizes specialty reviews, society guidelines and cancer‑center materials provided above; available sources do not mention some practicalities such as exact insurance coverage, regional HRA access maps, or head‑to‑head randomized trials comparing all screening strategies (not found in current reporting) [13] [15].